Shopping Cart 0
Cart Subtotal
USD 0

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Muscarinic Acetylcholine Receptor M4 (CHRM4)-Pipeline Review, H2 2017'; Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies.

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.

The report 'Muscarinic Acetylcholine Receptor M4 (CHRM4)-Pipeline Review, H2 2017' outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 3 and 7 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Mouth and Dental Disorders and Ophthalmology which include indications Alzheimer's Disease, Schizophrenia, Psychosis, Amnesia, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Epilepsy, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Parkinson's Disease, Presbyopia, Rett Syndrome and Sialorrhoea.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)

The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects

The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it'smost promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Overview

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Companies Involved in Therapeutics Development

Anavex Life Sciences Corp

AstraZeneca Plc

Heptares Therapeutics Ltd

Karuna Pharmaceuticals Inc

NeuroHealing Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Drug Profiles

(aceclidine + tropicamide)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ANAVEX-273 + donepezil hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(trospium chloride + xanomeline)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANAVEX-273-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-0016878-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0527-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0527f-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0559-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSX-0559f-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tropicamide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0467154-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-6000918-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Dormant Products

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Discontinued Products

Muscarinic Acetylcholine Receptor M4 (CHRM4)-Product Development Milestones

Featured News & Press Releases

Nov 04, 2017: Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer'sDisease Treatment ANAVEX2-73 at 2017 Clinical Trials on Alzheimer'sDisease Meeting

Oct 30, 2017: Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation's Parkinson's Disease Therapeutics Conference

Oct 27, 2017: Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS

Oct 12, 2017: Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX2-73 in Mild-to-Moderate Alzheimer'sDisease Patients

Sep 05, 2017: Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX 2-

Aug 31, 2017: First Subject Dosed in Phase 1 Clinical Study of Novel Selective MUSCARINIC M4 Agonist in Development to Treat Major Symptoms of Alzheimers Disease

Jul 20, 2017: Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board

May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference

May 19, 2017: Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings

Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in

Dec 15, 2016: Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimer's

Dec 08, 2016: Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer'sDisease Patients

Nov 22, 2016: Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer'sDisease

Nov 14, 2016: NeuroSolis Presented Data on NSX-0527 at Annual Meeting of the Society of Neuroscience

Sep 28, 2016: Anavex Compound to be Tested in Biogen Neurological Protection Model

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Anavex Life Sciences Corp, H2 2017

Pipeline by AstraZeneca Plc, H2 2017

Pipeline by Heptares Therapeutics Ltd, H2 2017

Pipeline by Karuna Pharmaceuticals Inc, H2 2017

Pipeline by NeuroHealing Pharmaceuticals Inc, H2 2017

Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Anavex Life Sciences Corp

AstraZeneca Plc

Heptares Therapeutics Ltd

Karuna Pharmaceuticals Inc

NeuroHealing Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd